Table 1.
Response of bone metastases to PRRT according to various baseline characteristics.Regression = complete, partial or minor response (CR, PR or MR)
| Variable | N | Regression (%) | p |
|---|---|---|---|
| Total | 68 | 33 (48.5%) | |
| Tumor type | |||
| P-NET | 23 | 14 (60.8%) | 0.201 |
| other GEP NET | 45 | 19 (42.2%) | |
| Performance status | |||
| KPS ≤70 | 18 | 10 (55%) | 0.586 |
| KPS >70 | 50 | 23 (46%) | |
| CgA | 0.025 | ||
| ≤600 ng/ml | 36 | 22 (61.1%) | |
| >600 ng/ml | 32 | 11 (34.3%) | |
| NSE | 0.799 | ||
| ≤15 ng/ml | 23 | 12 (52.2%) | |
| >15 ng/ml | 45 | 21 (46%) | |
| Ki67 index | 0.786 | ||
| ≤10% | 50 | 25 (50%) | |
| >10% | 18 | 8 (44%) | |
| Number of lesions | 0.635 | ||
| Few (≤10) | 37 | 19 (51.3%) | |
| multiple | 31 | 14 (45.2%) |
P-NET, pancreatic NET; KPS, Karnofsky performance score; CgA, chromogranin A; NSE, neuron-specific enolase.